Amikacin Dosing Adjustment in Critically Ill Oncologic Patients: A Study with Real-World Patients, PBPK Analysis, and Digital Twins
Authors:
- Juliana Queiroz da SilvaJSJuliana Queiroz da Silva
- Natália Valadares de MoraesNatália Valadares de Moraes
- Rita EstrelaRERita Estrela
- Diogenes CoelhoDCDiogenes Coelho
- Diego FerianiDFDiego Feriani
- Karen MigottoKMKaren Migotto
- Pedro CarusoPCPedro Caruso
- Ivan Leonardo França e SilvaISIvan Leonardo França e Silva
- Daiane de Araujo OliveiraDODaiane de Araujo Oliveira
- João Paulo TellesJTJoão Paulo Telles
- Fernanda de Lima MoreiraFernanda de Lima Moreira
Open Access
- 24 February 2025
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (3) , 297
Abstract
Background/Objectives: Guidelines recommend adjusting amikacin dosing based on patients’ renal function. Nevertheless, for critically ill cancer patients, the renal function equations based on serum creatinine levels have low or no correlation with amikacin clearance. Considering this, using real-world data, we built an amikacin PBPK model to predict amikacin plasma concentrations in critically ill oncologic patients stratified by renal impairment levels. Further, the model was applied for dose stratification and individualization (digital twin strategy) in this population. Methods: In the Therapeutic Drug Monitoring (TDM) study, 368 amikacin pharmacokinetic analyses from 184 critically ill cancer patients were enrolled in three cohorts. A full-body PBPK model was developed using PK-Sim v. 11.3. Results: The final PBPK model accounted for two groups of critically ill cancer patients with mild (creatinine clearance; CLcr ≥ 60 mL/min) or severe (CLcr < 60 mL/min) renal dysfunction. In the dose stratification strategy, at the 7th dose, cancer patients with CLcr ≥ 60 mL/min under regimens 20 mg/kg (q24h); 25 mg/kg (q24h); 25 mg/kg (q48h); and 30 mg/kg (q72h) have probability of ≥69% of the patients achieving the efficacy target (AUC/MIC > 80, MIC of 4 mg/L), while cancer patients with CLcr < 60 mL/min under regimens 7.5 mg/kg (q24h); 15 mg/kg (q24h); 15 mg/kg (q48h); and 20 mg/kg (q36h) have ≥90% probability of achieving the same efficacy target. Conclusions: Our MIPD approach demonstrates potential in optimizing amikacin dosing for critically ill cancer patients. However, it does not eliminate the need for TDM due to unexplained variability still not accounted for by the PBPK model.Keywords
Funding Information
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (E-26/260.325/2022)
This publication has 29 references indexed in Scilit:
- Prognostic and risk factor analysis of cancer patients after unplanned ICU admission: a real-world multicenter studyScientific Reports, 2023
- Tutorial on model selection and validation of model input into precision dosing software for model‐informed precision dosingCPT: Pharmacometrics & Systems Pharmacology, 2023
- Failure to predict amikacin elimination in critically ill patients with cancer based on the estimated glomerular filtration rate: applying PBPK approach in a therapeutic drug monitoring studyEuropean Journal of Clinical Pharmacology, 2023
- Delineating gene–environment effects using virtual twins of patients treated with clozapineCPT: Pharmacometrics & Systems Pharmacology, 2022
- Prediction of pharmacokinetics and pharmacodynamics of trelagliptin and omarigliptin in healthy humans and in patients with renal impairment using physiologically based pharmacokinetic combined DPP-4 occupancy modelingBiomedicine & Pharmacotherapy, 2022
- Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic AnalysisEuropean Journal of Drug Metabolism and Pharmacokinetics, 2021
- Physiologically‐Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry PerspectiveClinical Pharmacology & Therapeutics, 2020
- Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#Intensive Care Medicine, 2020
- Virtual Twins: Understanding the Data Required for Model‐Informed Precision DosingClinical Pharmacology & Therapeutics, 2020
- Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic StudiesClinical Pharmacokinetics, 2016